Akebia Therapeutics: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating

In a report released on May 9, Roanna Ruiz from Leerink Partners reiterated a Buy rating on Akebia Therapeutics (AKBA – Research Report), with a price target of $7.00.

Roanna Ruiz’s rating is based on Akebia Therapeutics’ strong financial performance and promising future prospects. The company reported first-quarter 2025 revenues of approximately $57 million, significantly surpassing both FactSet consensus and internal estimates. This impressive performance was driven by the successful launch of Vafseo, which generated around $12 million in its first quarter, exceeding management’s guidance and expectations.
Additionally, Auryxia’s revenues were notably higher than anticipated, reinforcing confidence in the company’s growth trajectory. The strategic positioning of Vafseo in the CKD dialysis anemia market, along with its potential expansion into CKD non-dialysis, presents substantial growth opportunities. The company’s solid cash position and management’s proactive steps towards future trials further support the Buy rating, as these factors indicate a well-prepared pathway to profitability.